Literature DB >> 10636336

A regulatory perspective on pharmacokinetic/pharmacodynamic modelling.

S G Machado1, R Miller, C Hu.   

Abstract

We present an integrated summary from statistical and pharmacological perspectives of pharmacokinetic/pharmacodynamic (PK/PD) modelling and its use in drug development and regulation for guiding appropriate dosing. An overview of the technical aspects of PK/PD modelling describes how structural models are constructed and refined using pharmacokinetic and pharmacodynamic principles and how random effects models are used to account for individual differences in desired (and undesired) responses due to patient characteristics. Lastly, we describe applications of PK/PD modelling for the purposes of drug labelling, for resolving a safety concern, and for improving therapeutic monitoring of anaesthetic depth during surgery.

Entities:  

Mesh:

Year:  1999        PMID: 10636336     DOI: 10.1177/096228029900800304

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  7 in total

Review 1.  Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.

Authors:  J V Gobburu; P J Marroum
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Authors:  Ch van Kesteren; R A A Mathôt; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 3.  Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Authors:  Wayne A Colburn; Jean W Lee
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 5.  Integrated pharmacokinetics and pharmacodynamics in drug development.

Authors:  Jasper Dingemanse; Silke Appel-Dingemanse
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

Review 7.  Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.

Authors:  Tony K L Kiang; Catherine M T Sherwin; Michael G Spigarelli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.